# Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

> **NCT05717582** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 47 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Castration-Sensitive Prostate Cancer

## Interventions

- **DRUG:** apalutamide
- **DRUG:** androgen deprivation therapy
- **PROCEDURE:** cytoreductive radical prostatectomy with/without pelvic lymph node dissection
- **RADIATION:** metastasis-directed therapy with radiation

## Key facts

- **NCT ID:** NCT05717582
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05717582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05717582, "Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05717582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*